Feb 13, 2026

# Evaluation of drug sensitivity in patient-derived MTSs

DOI
https://dx.doi.org/10.17504/protocols.io.rm7vze2yxvx1/v1

Zhe Zhao[1]

[1]CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Jiangsu, 215123, China.

MTS

Guangli Suo





**DOI:** https://dx.doi.org/10.17504/protocols.io.rm7vze2yxvx1/v1

**Protocol Citation:** Zhe Zhao 2026. Evaluation of drug sensitivity in patient-derived MTSs. **protocols.io** https://dx.doi.org/10.17504/protocols.io.rm7vze2yxvx1/v1

**Protocol status:** Working
**We use this protocol and it's working**

**Created:** February 13, 2026

**Last Modified:** February 13, 2026

**Protocol Integer ID:** 243174

**Keywords:** mts model for drug susceptibility testing, drug susceptibility testing, evaluation of drug sensitivity, drug sensitivity, derived mtss, mts model, mtss, mtss the detailed process, mt

**Funders Acknowledgements:**
**National Natural Science Foundation of China**
Grant ID: 82202345

## Abstract

The detailed process of using the MTS model for drug susceptibility testing.

## Materials

96-well plate, SG-Medium, Celltiter-Glo reagent (Vazyme), Synergy plate reader (BioTek)

## Evaluation of drug sensitivity in patient-derived MTSs

1 Fifty collected MTSs were aliquoted into each well of a 96-well plate. Based on the *SR_70% cutoff value for each individual chemotherapy drug and clinical chemotherapy regimens, the MTSs were treated with control vehicles, single chemotherapy drugs, or drug combinations (e.g., E-T: 0.1 μM Epirubicin + 10 nM Docetaxel; EC-T: 0.1 μM Epirubicin + 0.56 μM Palifosfamide + 10 nM Docetaxel; EC-THP: 0.1 μM Epirubicin + 0.56 μM Palifosfamide + 10 nM Docetaxel + 10 μg/mL Trastuzumab and Pertuzumab; TCbHP: 10 nM Docetaxel + 3.16 μM Carboplatin + 10 μg/mL Trastuzumab and Pertuzumab) in a volume of SG-Medium (50 μL).*

2 After three days of incubation, 50 μL Celltiter-Glo reagent (Vazyme) was added to each well to test the MTS survival rate (_SR_). The MTSs were incubated at room temperature for 10 min, followed by acquiring viability readings using a Synergy plate reader (BioTek).